Peptide Receptor Radionuclide Therapy in Thyroid Cancer

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2022 Jun 17

PMID 35712243

Authors

Sriram Gubbi

Christian A Koch

Joanna Klubo-Gwiezdzinska

Affiliations

Soon will be listed here.

Abstract

The treatment options that are currently available for management of metastatic, progressive radioactive iodine (RAI)-refractory differentiated thyroid cancers (DTCs), and medullary thyroid cancers (MTCs) are limited. While there are several systemic targeted therapies, such as tyrosine kinase inhibitors, that are being evaluated and implemented in the treatment of these cancers, such therapies are associated with serious, sometimes life-threatening, adverse events. Peptide receptor radionuclide therapy (PRRT) has the potential to be an effective and safe modality for treating patients with somatostatin receptor (SSTR)+ RAI-refractory DTCs and MTCs. MTCs and certain sub-types of RAI-refractory DTCs, such as Hürthle cell cancers which are less responsive to conventional modalities of treatment, have demonstrated a favorable response to treatment with PRRT. While the current literature offers hope for utilization of PRRT in thyroid cancer, several areas of this field remain to be investigated further, especially head-to-head comparisons with other systemic targeted therapies. In this review, we provide a comprehensive outlook on the current translational and clinical data on the use of various PRRTs, including diagnostic utility of somatostatin analogs, theranostic properties of PRRT, and the potential areas for future research.

Citing Articles

Comprehensive Review of the Imaging Recommendations for Diagnosis, Staging, and Management of Thyroid Carcinoma.

Chakrabarty N, Mahajan A, Basu S, DCruz A J Clin Med. 2024; 13(10).

PMID: 38792444 PMC: 11122658. DOI: 10.3390/jcm13102904.

Significant reduction of activity retention in the kidneys via optimized linker sequences in radiohybrid-based minigastrin analogs.

Holzleitner N, Fischer S, Maniyankerikalam I, Beck R, Lapa C, Wester H EJNMMI Res. 2024; 14(1):23.

PMID: 38429609 PMC: 10907560. DOI: 10.1186/s13550-024-01087-5.

Somatostatin Receptor Type 2 and Thyroid-Stimulating Hormone Receptor Expression in Oncocytic Thyroid Neoplasms: Implications for Prognosis and Treatment.

Gillis A, Zheng-Pywell R, McLeod C, Wang D, Ness J, Guenter R Mod Pathol. 2023; 36(12):100332.

PMID: 37716507 PMC: 10843045. DOI: 10.1016/j.modpat.2023.100332.

Sternum Metastases: From Case-Identifying Strategy to Multidisciplinary Management.

Carsote M, Terzea D, Vasilescu F, Cucu A, Ciuche A, Nistor C Diagnostics (Basel). 2023; 13(16).

PMID: 37627957 PMC: 10453928. DOI: 10.3390/diagnostics13162698.

The Effects of Peptide Receptor Radionuclide Therapy on the Neoplastic and Normal Pituitary.

Marques P Cancers (Basel). 2023; 15(10).

PMID: 37345047 PMC: 10216433. DOI: 10.3390/cancers15102710.

References

Haslinghuis L, Krenning E, de Herder W, Reijs A, Kwekkeboom D . Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest. 2001; 24(6):415-22. DOI: 10.1007/BF03351041. View

Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P . In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med. 2002; 32(2):148-55. DOI: 10.1053/snuc.2002.31565. View

Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P . Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999; 26(11):1439-47. View

Bergsma H, van Vliet E, Teunissen J, Kam B, de Herder W, Peeters R . Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Best Pract Res Clin Gastroenterol. 2013; 26(6):867-81. DOI: 10.1016/j.bpg.2013.01.004. View

. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159(3):676-90. PMC: 4243044. DOI: 10.1016/j.cell.2014.09.050. View

Ameri P, Ferone D . Diffuse endocrine system, neuroendocrine tumors and immunity: what's new?. Neuroendocrinology. 2012; 95(4):267-76. DOI: 10.1159/000334612. View

Giammarile F, Houzard C, Bournaud C, Hafdi Z, Sassolas G, Borson-Chazot F . Diagnostic management of suspected metastatic thyroid carcinoma: clinical value of octreotide scintigraphy in patients with negative high-dose radioiodine scans. Eur J Endocrinol. 2004; 150(3):277-83. DOI: 10.1530/eje.0.1500277. View

Araque K, Gubbi S, Klubo-Gwiezdzinska J . Updates on the Management of Thyroid Cancer. Horm Metab Res. 2020; 52(8):562-577. PMC: 7415555. DOI: 10.1055/a-1089-7870. View

Kelkar S, Reineke T . Theranostics: combining imaging and therapy. Bioconjug Chem. 2011; 22(10):1879-903. DOI: 10.1021/bc200151q. View

10.

Vyakaranam A, Crona J, Norlen O, Granberg D, Garske-Roman U, Sandstrom M . Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with Lu-DOTATATE. Cancers (Basel). 2019; 11(7). PMC: 6678507. DOI: 10.3390/cancers11070909. View

11.

Garin E, Devillers A, Le Cloirec J, Bernard A, Lescouarch J, Herry J . Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake. Eur J Nucl Med. 1998; 25(7):687-94. DOI: 10.1007/s002590050270. View

12.

Taelman V, Radojewski P, Marincek N, Ben-Shlomo A, Grotzky A, Olariu C . Upregulation of Key Molecules for Targeted Imaging and Therapy. J Nucl Med. 2016; 57(11):1805-1810. DOI: 10.2967/jnumed.115.165092. View

13.

Assadi M, Ahmadzadehfar H . Lu-DOTATATE and Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment. World J Nucl Med. 2020; 18(4):406-408. PMC: 6945353. DOI: 10.4103/wjnm.WJNM_112_18. View

14.

Burgus R, Ling N, Butcher M, Guillemin R . Primary structure of somatostatin, a hypothalamic peptide that inhibits the secretion of pituitary growth hormone. Proc Natl Acad Sci U S A. 1973; 70(3):684-8. PMC: 433335. DOI: 10.1073/pnas.70.3.684. View

15.

Tenenbaum F, Lumbroso J, Schlumberger M, Caillou B, Fragu P, Parmentier C . Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma. J Nucl Med. 1995; 36(5):807-10. View

16.

Czepczynski R, Matysiak-Grzes M, Gryczynska M, Baczyk M, Wyszomirska A, Stajgis M . Peptide receptor radionuclide therapy of differentiated thyroid cancer: efficacy and toxicity. Arch Immunol Ther Exp (Warsz). 2014; 63(2):147-54. PMC: 4359293. DOI: 10.1007/s00005-014-0318-6. View

17.

Hu S, Helman S, Hanly E, Likhterov I . The role of surgery in anaplastic thyroid cancer: A systematic review. Am J Otolaryngol. 2017; 38(3):337-350. DOI: 10.1016/j.amjoto.2017.02.005. View

18.

Wild D, Fani M, Behe M, Brink I, Rivier J, Reubi J . First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med. 2011; 52(9):1412-7. DOI: 10.2967/jnumed.111.088922. View

19.

Zatelli M, Piccin D, Tagliati F, Bottoni A, Luchin A, Vignali C . Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. J Clin Endocrinol Metab. 2006; 91(6):2218-24. DOI: 10.1210/jc.2006-0334. View

20.

Coca-Pelaz A, Rodrigo J, Shah J, Sanabria A, Al Ghuzlan A, Silver C . Hürthle Cell Carcinoma of the Thyroid Gland: Systematic Review and Meta-analysis. Adv Ther. 2021; 38(10):5144-5164. DOI: 10.1007/s12325-021-01876-7. View